中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
25期
19-20
,共2页
腋窝淋巴结转移%乳腺癌%辅助化疗%敏感基因
腋窩淋巴結轉移%乳腺癌%輔助化療%敏感基因
액와림파결전이%유선암%보조화료%민감기인
Axillary lymph node metastasis%Breast cancer%Neoadjuvant chemotherapy%Sensitivity gene
目的：探讨腋窝淋巴结转移乳腺癌术后辅助化疗效果及敏感基因分析。方法该次整群选取98例腋窝淋巴结转移乳腺癌术后的患者均为该院2010年5月-2014年5月收治,应用第三代基因测序仪对乳腺癌基因突变情况进行检测,并就化疗敏感性基因进行筛选。结果该次选取的淋巴结转移乳腺癌98例,检测出PIK3CA、MLH1、TP53基因突变,PIK3CA基因突变48例,占48.9%,<50岁的40患者,基因突变率为65%,>50岁58例中,基因突变率为37.9%,差异有统计学意义(P<0.05)。突变趋势在年轻患者中应用较明显,经统计示Ⅱ期44例,基因突变率为44.9%；Ⅲ期54例,基因突变率为55.1%。差异有统计学意义(r=2.184,P<0.05)。该次选取的98例患者中,CR8例,PR49例,SD22,PD19,总有效率58.2%。结论观察腋窝淋巴结转移乳腺癌术后辅助化疗疗效,并对敏感基因进行研究,利于治疗方案的制定,对保障患者预后的改善有非常重要的意义,值得临床引起重视。 PIK3CA为术后辅助化疗应用AC-D方案的较为敏感基因。
目的：探討腋窩淋巴結轉移乳腺癌術後輔助化療效果及敏感基因分析。方法該次整群選取98例腋窩淋巴結轉移乳腺癌術後的患者均為該院2010年5月-2014年5月收治,應用第三代基因測序儀對乳腺癌基因突變情況進行檢測,併就化療敏感性基因進行篩選。結果該次選取的淋巴結轉移乳腺癌98例,檢測齣PIK3CA、MLH1、TP53基因突變,PIK3CA基因突變48例,佔48.9%,<50歲的40患者,基因突變率為65%,>50歲58例中,基因突變率為37.9%,差異有統計學意義(P<0.05)。突變趨勢在年輕患者中應用較明顯,經統計示Ⅱ期44例,基因突變率為44.9%；Ⅲ期54例,基因突變率為55.1%。差異有統計學意義(r=2.184,P<0.05)。該次選取的98例患者中,CR8例,PR49例,SD22,PD19,總有效率58.2%。結論觀察腋窩淋巴結轉移乳腺癌術後輔助化療療效,併對敏感基因進行研究,利于治療方案的製定,對保障患者預後的改善有非常重要的意義,值得臨床引起重視。 PIK3CA為術後輔助化療應用AC-D方案的較為敏感基因。
목적：탐토액와림파결전이유선암술후보조화료효과급민감기인분석。방법해차정군선취98례액와림파결전이유선암술후적환자균위해원2010년5월-2014년5월수치,응용제삼대기인측서의대유선암기인돌변정황진행검측,병취화료민감성기인진행사선。결과해차선취적림파결전이유선암98례,검측출PIK3CA、MLH1、TP53기인돌변,PIK3CA기인돌변48례,점48.9%,<50세적40환자,기인돌변솔위65%,>50세58례중,기인돌변솔위37.9%,차이유통계학의의(P<0.05)。돌변추세재년경환자중응용교명현,경통계시Ⅱ기44례,기인돌변솔위44.9%；Ⅲ기54례,기인돌변솔위55.1%。차이유통계학의의(r=2.184,P<0.05)。해차선취적98례환자중,CR8례,PR49례,SD22,PD19,총유효솔58.2%。결론관찰액와림파결전이유선암술후보조화료료효,병대민감기인진행연구,리우치료방안적제정,대보장환자예후적개선유비상중요적의의,치득림상인기중시。 PIK3CA위술후보조화료응용AC-D방안적교위민감기인。
Objective To investigate the effect of chemotherapy in axillary lymph node analysis and sensitive gene adjuvant and metastatic breast cancer after operation. Methods The 98 cases with axillary lymph node metastasis of postoperative breast cancer patients. All of our hospital from May 2010 to May 2014, using the third generation of gene sequencing of the breast cancer gene mutations were detected, and the chemotherapy sensitivity of gene screening. Results The selection of the lymph node metastasis of breast carcinoma in 98 cases, the detection of PIK3CA, MLH1, TP53 gene mutation, the mutation of PIK3CA gene in 48 cases, accounting for 48.9%, and negatively correlated with age, <50 years old in 40 patients, the mutation rate was 65%, >50 years old in 58 cases, the mutation rate was 37.9%, there was statistical differentiation (P<0.05). Application of mutation trend in young pa-tients is significantly positive correlation with clinical stage, pathological, statistics indicated that there were 44 cases of stage II, the mutation rate was 44.9%; 54 cases in stage III, the mutation rate was 55.1%. There was significant difference (r=2.184, XP<0.05). In 98 cases the selected patients, CR8 cases, PR49 cases, SD22, PD19, the total efficiency of 58.2%. Conclusion The axil-lary lymph node metastasis of breast cancer neoadjuvant chemotherapy effect after operation were observed, and the research on sensitive genes, to develop a treatment plan, has very important significance to ensure improve the prognosis of patients, is worthy of clinical attention. More sensitive PIK3CA gene adjuvant chemotherapy for postoperative application of AC-D scheme.
